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Abstract
Background: Tauopathies are a major group of neurodegenerative disorders characterised by the 
presence of tau-immunoreactive inclusions in the cytoplasm of neurons and glia. The spread of 
pathogenic tau along neuroanatomical pathways may play a significant role in the pathogenesis 
of neurodegenerative disorders. It is hypothesised that such a spread of tau along neuroanatomical 
pathways would give rise to a characteristic spatial pattern of the tau-immunoreactive neuronal 
cytoplasmic inclusions (NCI) in affected tissue.
Methods: The aim of this study was to investigate this hypothesis by comparing the spatial 
patterns of NCI in regions of the cerebral cortex in eight different tauopathies: Alzheimer's disease, 
argyrophilic grain disease, chronic traumatic encephalopathy, corticobasal degeneration, 
frontotemporal dementia with parkinsonism linked to chromosome 17, Guam parkinsonism- 
dementia complex, Pick's disease, and progressive supranuclear palsy. 
Results: Regardless of disorder, tau isoform, or inclusion morphology, the NCI were most 
frequently aggregated into clusters, which were regularly distributed parallel to the pia mater. 
In many regions, the regularly distributed clusters of NCI range in size (400–800 µm) 
approximating to the dimension of cell columns associated with the cortico-cortical pathways. 
Conclusion: The presence of regularly distributed clusters of NCI in the cortex of all eight 
tauopathies suggests an association between the pathology and the cortico-cortical pathways 
and is consistent with the pathogenic spread of tau along these connections. Hence, treatments 
designed to protect the cortex from this spread may be applicable across many tauopathies.
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INTRODUCTION
The formation of inclusion bodies in the 
cytoplasm of neurons, also known as neuronal 
cytoplasmic inclusions (NCI), is a typical 
pathological feature of neurodegenerative 
disease.1-5 In many disorders, the inclusion 
bodies contain the microtubule-associated 
tau protein and are therefore referred to as 
tauopathies.2 Several disorders, both common 
and rare, are classified within this group, 
including the most common, Alzheimer’s disease 
(AD),6 as well as argyrophilic grain disease 
(AGD),7-10 chronic traumatic encephalopathy 
(CTE),11 corticobasal degeneration (CBD),12-14 
frontotemporal dementia with parkinsonism 
linked to chromosome 17 (FTDP-17),15 Guam 
parkinsonism-dementia complex (GPDC),16 Pick’s 
disease (PiD),17 and progressive supranuclear 
palsy (PSP).18-20
The molecular composition of pathogenic tau 
varies between the different tauopathies. Tau 
is encoded by the tau gene on chromosome 17, 
and alternative splicing of exons 2, 3, and 10 
results in six possible isoforms.21 Tau resulting 
from alternative splicing inclusion of exon 10 is 
known as 4-repeat (4R) tau, while tau lacking 
exon 10 is referred to as 3-repeat (3R) tau.2 
Individual tauopathies are characterised by 
inclusions containing differing proportions of 3R 
and 4R tau. Hence, NCI in PiD are characterised 
almost exclusively by 3R tau;22 those in AGD, 
CBD, and PSP by 4R tau;1,4,23,24 and in AD, CTE, 
and GPDC, the inclusions have a more complex 
composition containing both 3R and 4R tau 
in differing proportions.16,25 FTDP-17 has a 
particularly complex tau pathology in which 
different individuals may predominantly 
exhibit either a 3R or 4R tau pathology and 
proportions of the two may vary. Different NCI 
morphologies are also present, the majority being 
either flame-shaped neurofibrillary tangles (NFT), 
predominantly found in AGD, AD, CBD, CTE, 
and FTDP-17, or globose, as present in the Pick 
bodies of PiD. By contrast, PSP may have both 
flame-shaped and globose NFT.26 Hence, NCI is 
a collective term for all NCI in the tauopathies, 
but there are also specific names applied to 
specific inclusions in certain disorders such as 
NFT and Pick bodies.
It is believed that there are relatively few 
cellular pathways contributing to cell death in 
neurodegenerative disease27,28 and, consequently, 
the tauopathies are likely to have pathological 
mechanisms in common.  One common feature 
of these disorders may be the pathogenic 
spread of tau along neuro-anatomical 
pathways.29 Recent research suggests that 
several pathogenic proteins, including tau, 
α-synuclein, amyloid β (Aβ), and the disease 
form of prion protein, can be secreted 
from cells, enter other cells, and seed small 
intracellular aggregates within these cells.29,30 
This raises the possibility, as first suggested 
by Hawkes et al.31 with specific reference to 
the synucleinopathy Parkinson’s disease,31 that 
pathogenic agents may be propagated through 
the brain along neuro-anatomical pathways. 
If pathogenic tau spreads from cell to cell in 
tauopathies, then the resulting NCI would exhibit 
a spatial arrangement pattern in the tissue that 
reflects this spread.32 Nonrandom distributions 
of the NCI have been observed previously in 
various tauopathies, which lends some support 
to this hypothesis.33-35 The objective of the 
present study was, therefore, to compare 
the spatial patterns of the respective 
tau-immunoreactive NCI in the cerebral cortex 
of eight different tauopathies (AGD, AD, CBD, 
CTE, FTDP-17, GPDC, PiD, and PS) and to answer 
two questions: 
1. Do the NCI exhibit similar patterns of spatial 
distribution across different tauopathies?
2. Could these spatial patterns be the 
consequence of cell-to-cell spread of 
pathogenic tau along neuroanatomical 
pathways? 
MATERIALS AND METHODS
Cases
Cases of AD (n=6; mean age: 78 years; standard 
deviation [SD]: 9.2), CBD (n=12; mean age: 
90 years; SD: 9.7), PiD (n=10; mean age: 65 years; 
SD: 11.3), and PSP (n=8; mean age: 73 years; 
SD: 7.4) were obtained from the Brain Bank, 
Department of Neuropathology, Institute of 
Psychiatry, King’s College, London, UK.
AGD (n=25; mean age: 90 years; SD=9.7) and 
FTDP-17 (n=3; mean age: 77 years; SD: 4.7) 
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cases were obtained from the Departments of 
Neurology and Pathology and Immunology, 
Washington University School of Medicine, St. 
Louis, Missouri, USA.
CTE (n=11; mean age: 70 years; SD: 6.4) and 
GPDC (n=3; mean age: 77 years; SD: 0.71) cases 
were obtained from Boston University Chronic 
Traumatic Encephalopathy Center, Boston, 
Massachusetts, USA (VA-BU-CLF Brain Bank). 
Cases were diagnosed using current consensus 
criteria for AD,36-39 AGD,40 CBD,41 CTE,11 FTDP-17,15 
GPDC,42 PiD,15 and PSP.43
Tissue Preparation
All procedures performed in these studies were 
in accordance with the ethical standards of the 
Institute of Psychiatry, London, UK; Human 
Studies Committee of Washington University 
School of Medicine, St Louis, Missouri, USA; 
and the Institutional Review Board of Boston 
University, Boston, Massachusetts, USA, 
and were carried out according to the 1964 
Declaration of Helsinki and later amendments. 
After death, the next-of-kin provided written 
consent for brain removal and retention for 
research studies. Brain tissue was preserved 
in buffered 10% formalin. Tissue blocks were 
taken from various cortical areas including 
the superior frontal gyrus (B8), the superior 
parietal lobule (B7), the inferior temporal gyrus 
(B22), the parahippocampal gyrus (B28), and 
the ambient gyrus (B27). 
Brain material was fixed in 10% phosphate 
buffered formal-saline and embedded in paraffin 
wax. Immunohistochemistry was performed 
on 6–8 µm sections using various anti-tau 
antibodies (AT8, PHF-1, TP70). Sections were 
also counterstained with haematoxylin to reveal 
the various types of neuronal and glial cells and 
establish the tissue boundaries. 
Morphometric Methods 
In each region of the cerebral cortex the NCI 
were counted along a strip of tissue located 
parallel to the pia mater, using between 32 
and 64, 50x250 µm sample fields arranged 
contiguously.44 The sample fields were located 
both in the upper (approximating to layers 
II/III) and lower (approximating to layers V/VI) 
cortex. The short edge of the sample field was 
orientated to be parallel with the pia mater 
and aligned with guidelines marked on the 
slide. Where cortical sections exhibited severe 
atrophy, as in PiD and CTE, only the upper 
cortical laminae were studied. The number of 
NCI present in each sample field was counted. 
NCI were measured in alkyltransferase rather 
than the argyrophilic grains for consistency 
with the other tauopathies, such as the NCI of 
AGD (tangles and pre-tangles), which are also 
characteristic features of the disease.7-10 
Data Analysis
Changes in density of inclusions along the 
tissue parallel to the tissue boundary were 
analysed using spatial pattern analysis.45-47 This 
method uses the variance–mean ratio (V:M) 
to determine whether NCI were distributed 
randomly (V:M=1), regularly (V:M<1), or were 
clustered (V:M>1) along a strip of tissue. Counts 
of NCI in adjacent sample fields were then 
added together successively to provide data 
for increasing field sizes (e.g., 50x250 µm, 
100x250 µm, and 200x250 µm) up to a size 
limited by the length of the strip sampled. V:M 
was then plotted against field size to determine 
whether the clusters of NCI were regularly or 
randomly distributed and to estimate the mean 
cluster size parallel to the tissue boundary. A V:M 
peak indicates the presence of regularly spaced 
clusters while an increase in V:M to an asymptotic 
level suggests the presence of randomly 
distributed clusters. The statistical significance 
of a peak was tested using t distribution.45 
Spatial patterns of inclusions in the various 
regions were classified into four categories: 
random, uniform or regular, regularly distributed 
clusters, and large-scale clusters without 
evidence of regular spacing. The frequency of 
regions in which regularly distributed clusters 
were in the size range 400–800 µm (i.e., the 
size of the columns of cells associated with the 
cortico-cortical pathways) was also determined. 
A more complex spatial pattern was evident 
in some regions in which smaller clusters of 
inclusions were aggregated into larger clusters 
and the frequency of this spatial pattern was 
also determined. Comparison of frequencies 
among disorders was made using chi-square 
contingency tables tests. Mean cluster size of 
the NCI was compared among disorders using 
a one-way analysis of variance (ANOVA) 
(STATISTICA™, Statsoft Inc., Tulsa, Oklahoma, USA) 
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followed by Tukey’s honestly significant difference 
post-hoc test. In each disorder, the correlation 
between cluster size of the inclusions, disease 
duration, and disease stage was tested.48-51
RESULTS
Examples of the spatial patterns exhibited by 
NCI in various tauopathies are shown in 
Figure 1. In AGD, the NCI (NFT) exhibited a 
V:M peak at a field size of 50 µm suggesting 
the presence of clusters of NFT, 50 µm in 
diameter, regularly distributed parallel to the 
pia mater. The V:M ratio of the NCI (NFT) in AD 
increased with field size, without reaching a 
peak, suggesting the presence of a large cluster 
of NFT at least 1,600 µm in diameter. The V:M 
ratio of the NCI (NFT) in CTE exhibited two 
V:M peaks at 50 µm and 400 µm suggesting 
clustering at two scales in the tissue.
A summary of the frequencies of the four types 
of spatial patterns exhibited by NCI in the eight 
tauopathies is shown in Table 1. Most frequently, 
the NCI were clustered (mean cluster size in 
the range of 200–1,600 µm) and were regularly 
distributed parallel to the pia mater. This spatial 
pattern was present in all eight tauopathies but 
varied in frequency from 36% of CTE regions 
to 73% in AD. Larger-scale clustering of NCI, 
without evidence of regular spacing, was also 
present, especially in PiD and CBD. In some 
disorders, including AGD, CTE, and PSP, the NCI 
were also randomly distributed in a proportion 
of regions.
Chi-square contingency table tests (Table 1) 
suggested that there were significant 
differences in the frequency of the various 
spatial patterns among tauopathies (χ2=100.69; 
21 degrees of freedom [DF]; p<0.001), with 
AGD, CTE, and PSP having regions exhibiting 
a higher proportion of random distributions, 
and PiD and CBD a higher proportion of regions 
with large-scale-clustering.
The Chi-square contingency table tests also 
indicated that there were significant differences 
among disorders characterised by different tau 
isoforms (χ2=32.04; 3 DF; p<0.01) with 3R tau 
PiD having the lowest proportion of random or 
regular and uniform distributions compared 
with the 4R tau disorders (AGD, CBD, PSP) 
(χ2=12.81; 3 DF; p<0.01) and those characterised 
by both 3R and 4R tau (AD, CTE, and GPDC) 
(χ2=19.88; 3 DF; p<0.001). In addition, the 3R/4R 
combination disorders had a higher frequency 
of uniform distributions compared with both 
PiD (3R tau) (χ2=19.88; 3 DF; p<0.001) and 4R 
disorders (χ2=12.54; 3 DF; p<0.01). 
There were also differences in the spatial 
patterns in disorders with predominantly flame-
shaped NFT (AGD, AD, PSP, and CBD) compared 
with PiD, which has predominantly round or 
oval inclusions (χ2=25.19; 2 DF; p<0.001), and 
with PSP, which has both morphologies 
(χ2=17.33; 6 DF; p<0.001), with regularly 
distributed clustering being more frequent in PiD.
The Chi-square contingency table tests also 
suggested there were similarities in spatial 
patterns in cases characterised by a genetic 
aetiology (FTDP-17) or associated with head 
trauma (CTE) (χ2=1.40; 3 DF; p>0.05), but both 
differed from the remaining disorders which 
have a more uncertain aetiology in which 
regular-spaced clusters are less frequent. In 
a significant proportion of brain regions in all 
disorders, especially PiD and CBD, the regularly 
distributed clusters of inclusion were in the size 
range 400–800 µm (Table 1). A more complex 
spatial pattern, in which smaller clusters were 
aggregated into larger clusters, was also 
evident, with the exception of CTE and PSP.
Mean cluster size of NCI (Figure 2), averaged 
over cortical regions, varied among disorders 
(F=16.95; p<0.001). Post-hoc tests suggested 
that cluster sizes were greater in AD than 
in all the other tauopathies, cluster size was 
significantly larger in PiD than in the other 
disorders with the exception of AD, and that 
size was greater in CBD than in AGD, CTE, 
or GPDC. No statistically significant correlations 
were observed between cluster size of the NCI 
and either disease duration or disease stage in 
any disorder.
DISCUSSION
There are a number of limitations to this study 
that should be considered when interpreting 
the results. The first point to consider is that 
different tau antibodies were used for the 
various tauopathies; however, no differences in 
density, type, or morphology of NCI have been 
observed between the tau antibodies used.33 
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A second consideration is that different 
anatomical pathways are affected in the 
different disorders and each of the cerebral 
cortex regions selected for study, mainly frontal 
and temporal lobe regions, may not reflect 
the critical regions in all disorders. Thirdly, 
different stages of disease progression are 
likely to be present within the various disorders. 
In an attempt to address the effect of disease 
stage, the correlation between cluster size of 
inclusions and disease duration and disease 
stage was investigated. The data, however, 
provided little evidence that cluster sizes 
altered consistently during the disease process, 
which could have been due to the small 
number of cases studied within each disease 
category. Finally, rare diseases, such as 
FTDP-17 and GPDC, were only represented by 
small numbers of cases and results for these 
tauopathies should be regarded as provisional.
The data suggest that NCI in the eight 
tauopathies, regardless of disorder, tau 
isoforms, aetiology, or inclusion morphology, 
were commonly clustered in regions of the 
cerebral cortex and, in a significant proportion 
of gyri, the clusters were regularly distributed 
parallel to the pia mater.34 However, the 
frequency of this spatial pattern varied among 
tauopathies, being most frequent in AD and 
least frequent in CTE and PSP. This spatial 
pattern was also present in disorders that 
had a prominent additional glial pathology 
(e.g., CBD35 and PSP26) or where an additional 
major molecular pathology was present, 
such as the Aβ deposits in AD. Variations 
in the overall frequency of different spatial 
patterns were also observed, the data suggest 
significant differences between AD, PiD, and 
CBD, in which regularly distributed clusters 
of inclusions were common and random 
distributions rare compared with AGD and PSP 
in which random distributions were significantly 
more common. 
A number of features of the observed spatial 
patterns are consistent with the development 
of NCI in association with the neuro-anatomical 
pathways of the cerebral cortex and most 
specifically the cortico-cortical pathways.45,52 
Figure 1: Pattern analysis plots showing examples of the spatial patterns exhibited by neuronal cytoplasmic 
inclusions in argyrophilic grain disease, chronic traumatic encephalopathy, and Alzheimer’s disease. 
AD: Alzheimer’s disease; AGD: argyrophilic grain disease; CTE: chronic traumatic encephalopathy. 
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In cortical regions, the cells of cortico-cortical 
projection origin are clustered and occur in 
bands that are regularly distributed along the 
cortex. Individual bands of cells traverse the 
cortical laminae and, in primate brains, vary in 
width in the range of 400–500 µm up to 
800–1,000 µm, depending on cortical region.53,54 
Although there was considerable variation in 
cluster sizes among disorders, the width of the 
NCI clusters and their distribution along the 
cortex is consistent with an association with 
these pathways, with three exceptions. The first 
exception was that in some regions the NCI 
occurred in clusters larger than 400–1,000 µm, 
with some clusters being >3,200 µm in diameter, 
especially in AD, PiD, and CBD. In a small 
number of regions, clustering occurred at 
more than one site with smaller clusters of NCI 
aggregated together. The larger and more 
complex clusters suggest that the smaller 
regularly distributed clusters of inclusions could 
coalesce to form larger aggregations as the 
disease progresses, a process which appears 
to be a feature of AD, PiD, and CBD resulting in 
especially large clusters in these disorders.45 
Another exception was that NCI were randomly 
distributed in some gyri, especially in AGD, CTE, 
and PSP. Random distributions are often the 
result of low densities of inclusions,34,55 which are 
likely to occur in the cortex in PSP, a primarily 
subcortical disorder.26 In AGD, by contrast, 
NCI may not be the most abundant tau 
pathology present in these cases, which are also 
characterised by significant aggregations of 
neuropil threads and argyrophilic grains.50,51,56
The size and distribution of the clusters of 
NCI in all the tauopathies studied suggested 
a close relationship in the cortex between 
the developing pathology and neuroanatomical 
pathways. The most likely explanation for this 
association is the spread of pathogenic tau 
among cortical regions along the cortico-cortical 
connections.29 However, differences in cluster 
size of the NCI were observed in different 
tauopathies, which suggests variation in the 
degree to which the cortical modules which 
comprise these connections were affected. 
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Figure 2: Mean cluster size of the neuronal cytoplasmic inclusions in the cerebral cortex of the eight tauopathies. 
One-way analysis of variance (ANOVA) (with Tukey’s honestly significant difference post-hoc test) analysis showed a 
cluster size of F=16.95 (p<0.001). Significant differences shown between groups: AD larger than all other tauopathies; 
PiD larger than all others except AD; and CBD larger than AGD, CTE, FTDP-17, GPDC, and PSP.
AD: Alzheimer’s disease; AGD: argyrophilic grain disease; CBD: corticobasal degeneration; CTE: chronic traumatic 
encephalopathy; FTDP-17: frontotemporal dementia with parkinsonism linked to chromosome 17; GPDC: Guam 
parkinsonism-dementia complex; PiD: Pick's disease; PSP: progressive supranuclear palsy.
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The largest clusters were observed in AD, PiD, 
and CBD, while the smallest were found in AGD, 
CTE, and PSP. Differences in cluster size could 
be attributable to: 
 > Difference in density of the NCI. 
 > Differences in the vulnerability of anatomical 
pathways to the spread of pathogenic tau, 
a more selective group of neurons being 
compromised in AGD, CTE, and PSP.
 > Differences in the rate of spread of pathogenic 
tau along neuroanatomical connections.
Propagation of pathogenic tau is not the 
only explanation for the results as they could 
represent intrinsic spatio-temporal-specific 
neuronal vulnerability affecting clusters of 
neurons and that not all stages in the proposed 
transfer have yet been demonstrated 
experimentally through cellular uptake, 
templated seeding, secretion, and overall transfer 
via synaptic and non-synaptic pathways.57
CONCLUSION
In conclusion, neurodegenerative disorders 
characterised by tau-immunoreactive NCI 
exhibit similar spatial patterns in regions of 
the cerebral cortex, consistent with their 
association with the degeneration of specific 
anatomical pathways. This association could 
reflect cell-to-cell spread of pathogenic tau 
in the tauopathies consistent with a common 
pattern of cortical neurodegeneration across 
disorders. Hence, it would be useful to trace 
the spatial pattern of inclusions along specific 
anatomical pathways in various tauopathies to 
test this hypothesis more rigorously. In addition, 
the data imply that different tauopathies 
may be amenable to similar interventions 
(e.g., immunotherapy that targets extracellular 
pathogenic tau) that could lead to its 
removal, thus preventing or slowing cell-to- 
cell propagation.58 
Chi-square contingency tests comparing totals of upper and lower cortex. Comparing all taupathies: χ2=100.69 
(21DF; p<0.001); comparing 3R tauopathies with 4R tauopathies: χ2=32.04 (6DF; p<0.001); 3R with 4R: χ2=12.81 
(3DF; p<0.01); 3R with 3R and 4R: χ2=19.88 (3DF; p<0.001); 4R with 3R and 4R: χ2=12.54 (3DF; p<0.01); comparing 
FTDP-17 and CTE with idiopathic tauopathies: χ2=46.01 (6DF; p<0.01); FTDP-17 with CTE: χ2=1.40 (3DF; p>0.05); 
FTDP-17 with idiopathic: χ2=8.63 (3DF; p<0.05); CTE with idiopathic: χ2=45.31 (3DF; p<0.001); Comparing different 
NCI morphologies: All disorders: χ2= 36.96 (6DF; p<0.001); PiD with PSP: χ2=25.19 (2DF; p<0.001); PSP with all other 
disorders: χ2=17.33 (3DF; p<0.001); PiD with all other disorders: χ2=15.08 (3DF; p<0.01). 
AD: Alzheimer’s disease; AGD: argyrophilic grain disease; CBD: corticobasal degeneration; CTE: chronic traumatic 
encephalopathy; DF: degrees of freedom; FTDP-17: frontotemporal dementia with parkinsonism linked to 
chromosome 17; GPDC: Guam parkinsonism-dementia complex; LC: large clusters; N: total number of cortical regions 
analysed for each disorder; NCI: neuronal cytoplasmic inclusion; NFT: neurofibrillary tangles; PB: Pick bodies;  
PiD: Pick's disease; PSP: progressive supranuclear palsy; RGC: regularly distributed clusters; U/RG: uniform or regular.
Table 1: Frequency of different types of spatial pattern exhibited by neuronal cytoplasmic inclusions in the upper 
and lower cortex in the various tauopathies.
Frequency of spatial pattern
Disorder NCI N Random U/RG RGC LC RGC (%) RGC (400–800 µm)
AD NFT 30 1 0 22 7 73 6
AGD NFT 61 15 2 30 9 49 3
CBD NCI 76 2 2 48 24 63 24
CTE NFT 42 11 11 15 5 36 6
FTDP-17 NFT 13 3 2 5 3 38 3
GPDC NFT 16 2 2 9 3 56 3
PiD PB 48 1 0 27 20 53 15
PSP NFT 23 11 0 10 2 43 2
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